SCHEMBL2440135

SCHEMBL2440135

O=C(Nc1noc2cccc(OCC(F)(F)F)c12)c1ccc(C(F)(F)F)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 2/20 0.46
KCNQ2 O43526 2/20 0.46
KCNE1 P15382 2/20 0.46
KCNQ1 P51787 2/20 0.46
TP53 P04637 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
CLK1 P49759 1/20 0.40
DYRK1A Q13627 1/20 0.40
STAT3 P40763 1/20 0.38
UGCG Q16739 1/20 0.38
SGMS2 Q8NHU3 4/20 0.38
MAPT P10636 2/20 0.37
KIT P10721 1/20 0.37
KDR P35968 1/20 0.37
FLT3 P36888 1/20 0.37
GSK3B P49841 1/20 0.37
F2RL3 Q96RI0 1/20 0.37
AR P10275 1/20 0.37
AURKA O14965 1/20 0.37
RPS6KB1 P23443 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2440764 0.92 TP53 (0.44) KCNQ3KCNQ2KCNE1KCNQ1TP53
SCHEMBL2438284 0.84 KCNQ3 (0.46) KCNQ3KCNQ2KCNE1KCNQ1TP53
SCHEMBL2440435 0.83 LCLAT1 (0.43) TP53SMN1; SMN2UGCGSGMS2F2RL3
SCHEMBL2438849 0.83 SMN1; SMN2 (0.45) TP53SMN1; SMN2UGCGMAPT
SCHEMBL2439122 0.82 UGCG (0.43) TP53SMN1; SMN2UGCGSGMS2AURKA
SCHEMBL2441155 0.80 UGCG (0.41) TP53SMN1; SMN2UGCGSGMS2LCLAT1
SCHEMBL2439200 0.80 PYGL (0.43) TP53SMN1; SMN2SGMS2LCLAT1
SCHEMBL2439755 0.78 TP53 (0.66) KCNQ3KCNQ2KCNE1KCNQ1TP53
Cyclohexane SCHEMBL2442882 0.77 KCNA5 (0.39) TP53SMN1; SMN2UGCGSGMS2MAPT
Cyclopropane SCHEMBL2441865 0.77 KCNA5 (0.39) TP53SMN1; SMN2UGCGSGMS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP claimed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO claimed
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 KCNQ3 1364/4885KCNQ2 1099/4885KCNE1 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.